
Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2024-2030
Description
Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2024-2030
The Immuno-oncology Clinical Trials Market size was estimated at USD 6.13 billion in 2023 and expected to reach USD 6.58 billion in 2024, at a CAGR 11.17% to reach USD 12.87 billion by 2030.
Global Immuno-oncology Clinical Trials Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Immuno-oncology Clinical Trials Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immuno-oncology Clinical Trials Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Immuno-oncology Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Exscientia PLC, F. Hoffmann-La Roche Ltd., ICON PLC, IO Biotech ApS, IQVIA Inc., Laboratory Corporation of America Holdings, Medpace, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Rubius Therapeutics, Inc., and Syneos Health, Inc..
Market Segmentation & Coverage
This research report categorizes the Immuno-oncology Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:
Design
Expanded Access Trials
Interventional Trials
Observational Trials
Phase
Phase I
Phase II
Phase III
Phase IV
Indication
Hematological Cancer
Solid Tumors
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Immuno-oncology Clinical Trials Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immuno-oncology Clinical Trials Market?
3. What are the technology trends and regulatory frameworks in the Immuno-oncology Clinical Trials Market?
4. What is the market share of the leading vendors in the Immuno-oncology Clinical Trials Market?
5. Which modes and strategic moves are suitable for entering the Immuno-oncology Clinical Trials Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Immuno-oncology Clinical Trials Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence of cancer and the growing adoption of targeted therapy
- 5.1.1.2. Growing significance of companion diagnostics in drug development
- 5.1.1.3. Rapidly increasing demand for personalized medicine
- 5.1.2. Restraints
- 5.1.2.1. Requirement of high capital investments and low cost-benefit ratio
- 5.1.3. Opportunities
- 5.1.3.1. Advancements in immuno-oncology testing
- 5.1.3.2. Increasing financial support from the government for cancer R&D
- 5.1.4. Challenges
- 5.1.4.1. Huge complexity in the production and manufacturing processes
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Immuno-oncology Clinical Trials Market, by Design
- 6.1. Introduction
- 6.2. Expanded Access Trials
- 6.3. Interventional Trials
- 6.4. Observational Trials
- 7. Immuno-oncology Clinical Trials Market, by Phase
- 7.1. Introduction
- 7.2. Phase I
- 7.3. Phase II
- 7.4. Phase III
- 7.5. Phase IV
- 8. Immuno-oncology Clinical Trials Market, by Indication
- 8.1. Introduction
- 8.2. Hematological Cancer
- 8.3. Solid Tumors
- 9. Americas Immuno-oncology Clinical Trials Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Immuno-oncology Clinical Trials Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.
- 10. South Korea
- 10.
- 11. Taiwan
- 10.
- 12. Thailand
- 10.
- 13. Vietnam
- 11. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.
- 10. Nigeria
- 11.
- 11. Norway
- 11.
- 12. Poland
- 11.
- 13. Qatar
- 11.
- 14. Russia
- 11.
- 15. Saudi Arabia
- 11.
- 16. South Africa
- 11.
- 17. Spain
- 11.
- 18. Sweden
- 11.
- 19. Switzerland
- 11.
- 20. Turkey
- 11.
- 21. United Arab Emirates
- 11.
- 22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. AstraZeneca PLC
- 13.1.2. BioNTech SE
- 13.1.3. Bristol Myers Squibb Company
- 13.1.4. Exscientia PLC
- 13.1.5. F. Hoffmann-La Roche Ltd.
- 13.1.6. ICON PLC
- 13.1.7. IO Biotech ApS
- 13.1.8. IQVIA Inc.
- 13.1.9. Laboratory Corporation of America Holdings
- 13.1.
- 10. Medpace, Inc.
- 13.1.
- 11. Merck KGaA
- 13.1.
- 12. Novartis AG
- 13.1.
- 13. Pfizer Inc.
- 13.1.
- 14. Rubius Therapeutics, Inc.
- 13.1.
- 15. Syneos Health, Inc.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
- FIGURE 2. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
- FIGURE 3. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET DYNAMICS
- FIGURE 7. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
- FIGURE 8. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
- FIGURE 10. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.